発表論文

Kawada R, Jonouchi T, Kagita A, Sato M, Hotta A, Sakurai H.

Establishment of quantitative and consistent in vitro skeletal muscle pathological models of myotonic dystrophy type 1 using patient-derived iPSCs. Sci Rep., 2023 Jan 11;13(1):94.

Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S.

Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng., 2023 Jan;7(1):24-37.

Watanabe K, Gee P, Hotta A.

Preparation of NanoMEDIC extracellular vesicles to deliver CRISPR-Cas9 ribonucleoproteins for genomic exon skipping. Methods Mol Biol., 2023;2587:427-453.

Park G, Shin M, Lee W, Hotta A, Kobayashi T, Kosodo Y.

Direct visualization of the transition status during neural differentiation by dual-fluorescent reporter human pluripotent stem cells. Stem Cell Reports, 2022 Sep 13;17(9):1903-1913.

Kitano Y, Nishimura S, Kato TM, Ueda A, Takigawa K, Umekage M, Nomura M, Kawakami A, Ogawa H, Xu H, Hotta A, Takasu N, Tsukahara M.

Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application. Mol Ther Methods Clin Dev, 2022 May 29;26:15-25.

Taha EA, Lee J, Hotta A.

Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. J Control Release., 2022 Jan 10;342:345-361.doi: 10.1016/j.jconrel.2022.01.013

Kenjo E, Hozumi H, Makita Y, Iwabuchi KA, Fujimoto N, Matsumoto S, Kimura M, Amano Y, Ifuku M, Naoe Y, Inukai N, Hotta A.

Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun., 2021 Dec 8;12(1):7101. doi: 10.1038/s41467-021-26714-w.

Xu H, Kita Y, Bang U, Gee P, Hotta A.

Optimized electroporation of CRISPR-Cas9/gRNA ribonucleoprotein complex for selection-free homologous recombination in human pluripotent stem cells. STAR Protocols., 2021 Nov 19; doi: 10.1016/j.xpro.2021.100965

Hashimoto R, Sakamoto A, Deguchi S, Yi R, Sano E, Hotta A, Takahashi K, Yamanaka S, Takayama K.

Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells. Mol Ther Nucleic Acids., 2021 Dec 3;26:1107-1114. doi: 10.1016/j.omtn.2021.10.016. Epub 2021 Oct 20.

Noda M, Tatsumi K, Matsui H, Matsunari Y, Sato T, Fukuoka Y,Hotta A, Okano T, Kichikawa K, Sugimoto M, Shima M, Nishio K.

Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model. Regen Ther., 2021 Sep 10;18:347-354. doi: 10.1016/j.reth.2021.08.009. eCollection 2021 Dec.

Okubo C, Narita M, Inagaki A, Nishikawa M, Hotta A, Yamanaka S, Yoshida Y.

Expression dynamics of HAND1/2 in in vitro human cardiomyocyte differentiation. Stem Cell Reports, 2021 Aug 10;16(8):1906-1922. doi: 10.1016/j.stemcr.2021.06.014. Epub 2021 Jul 22.

Uchimura T, Asano T, Nakata T, Hotta A, Sakurai H.

A muscle fatigue-like contractile decline was recapitulated using skeletal myotubes from Duchenne muscular dystrophy patient-derived iPSCs. Cell Rep Med., 2021 Jun 4;2(6):100298. doi: 10.1016/j.xcrm.2021.100298. eCollection 2021 Jun 15.

Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, Minagawa A, Ishikawa A, Yano H, Ishi T, Ito R, Goto M, Takahashi R, Uemura Y, Hotta A, Kaneko S.

Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng., 2021 May;5(5):429-440. doi: 10.1038/s41551-021-00730-z. Epub 2021 May 17.

Nalbandian M, Zhao M, Sasaki-Honda M, Jonouchi T, Lucena-Cacace A, Mizusawa T, Yasuda M, Yoshida Y, Hotta A, Sakurai H.

Characterization of hiPSC-Derived Muscle Progenitors Reveals Distinctive Markers for Myogenic Cell Purification Toward Cell Therapy. Stem Cell Reports, 2021 Apr 13;16(4):883-898. doi: 10.1016/j.stemcr.2021.03.004. Epub 2021 Apr 1.

Kagita A, Lung MSY, Xu H, Kita Y, Sasakawa N, Iguchi T, Ono M, Wang XH, Gee P, Hotta A.

Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein. Stem Cell Reports 16(4):985-996 (2021)

Yamada H, Shirata N, Makino S, Miyake T, Trejo JAO, Yamamoto-Nonaka K, Kikyo M, Empitu MA, Kadariswantiningsih IN, Kimura M, Ichimura K, Yokoi H, Mukoyama M, Hotta A, Nishimori K, Yanagita M, Asanuma K.

MAGI-2 orchestrates the localization of backbone proteins in the slit diaphragm of podocytes. Kidney Int., 2021 Feb;99(2):382-395. doi: 10.1016/j.kint.2020.09.027. Epub 2020 Nov 2.

Shimizu T, Mae SI, Araoka T, Okita K, Hotta A, Yamagata K, Osafune K.

A novel ADPKD model using kidney organoids derived from disease-specific human iPSCs. Biochem Biophys Res Commun., 4:1186-1194 (2020)

Kuraoka S, Tanigawa S, Taguchi A, Hotta A, Nakazato H, Osafune K, Kobayashi A, Nishinakamura R.　

PKD1-Dependent Renal Cystogenesis in Human Induced Pluripotent Stem Cell-Derived Ureteric Bud/Collecting Duct Organoids. J Am Soc Nephrol., 2020 Oct;31(10):2355-2371. doi: 10.1681/ASN.2020030378. Epub 2020 Aug 3.

Zhao M, Tazumi A, Takayama S, Takenaka-Ninagawa N, Nalbandian M, Nagai M, Nakamura Y, Nakasa M, Watanabe A, Ikeya M, Hotta A, Ito Y, Sato T, Sakurai H.

Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model. Stem Cell Reports, 2020 Jul 14;15(1):80-94. doi: 10.1016/j.stemcr.2020.06.004. Epub 2020 Jul 2.

Sasaki-Honda M, Kagita A, Jonouchi T, Araki T, Hotta A, Sakurai H.

Generation of a transgene-free iPSC line and genetically modified line from a facioscapulohumeral muscular dystrophy type 2 (FSHD2) patient with SMCHD1 p.Lys607Ter mutation. Stem Cell Res, 2020 Jun 24;47:101884. doi: 10.1016/j.scr.2020.101884

Gee P, Lung MSY, Okuzaki Y, Sasakawa N, Iguchi T, Makita Y, Hozumi H, Miura Y, Yang LF, Iwasaki M, Wang XH, Waller MA, Shirai N, Abe YO, Fujita Y, Watanabe K, Kagita A, Iwabuchi KA, Yasuda M, Xu H, Noda T, Komano J, Sakurai H, Inukai N, and Hotta A.

Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nature Communications, 2020 Mar 13; 11, 1334. doi: 10.1038/s41467-020-14957-y.

Luo J, Qin L, Zhao L, Gui L, Ellis MW, Huang Y, Kural MH, Clark JA, Ono S, Wang J, Yuan Y, Zhang SM, Cong X, Li G, Riaz M, Lopez C, Hotta A, Campbell S, Tellides G, Dardik A, Niklason LE, and Qyang Y.

Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs. Cell Stem Cell, 2020 Feb 6;26(2):251-261.e8. doi: 10.1016/j.stem.2019.12.012. Epub 2020 Jan 16.

Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, Akasaka M, Nakamura S, Higashi N, Xu H, Matsumoto T, Fujio K, Manz MG, Hotta A, Takizawa H, Eto K, Sugimoto N.

iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity. Stem Cell Reports, 2020 Jan 14;14(1):49-59. doi: 10.1016/j.stemcr.2019.11.011. Epub 2019 Dec 26.

Morisaka H*, Yoshimi K*, Okuzaki Y*, Gee P, Kunihiro Y, Sonpho E, Xu H, Sasakawa N, Naito Y, Nakada S, Yamamoto T, Sano S, Hotta A§, Takeda J§, and Mashimo T§.
(*: Co-1st author, §: Co-correspondance)

CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nature Communications, 2019 Dec 6; 10, 5302. doi: doi:10.1038/s41467-019-13226-x

Xu H*, Wang B*, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, Kitaoka F, Takahashi T, Okita K, Yoshida Y, Kaneko S§, and Hotta A§.
(*: Co-1st author, §: Co-correspondance)

Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell, 2019 Apr 4;24(4):566-578.e7. doi: 10.1016/j.stem.2019.02.005. Epub 2019 Mar 7.

Korogi Y, Gotoh S, Ikeo S, Yamamoto Y, Sone N, Tamai K, Konishi S, Nagasaki T, Matsumoto H, Ito I, Chen-Yoshikawa TF, Date H, Hagiwara M, Asaka I, Hotta A, Mishima M, Hirai T.

In vitro disease modeling of Hermansky-Pudlak syndrome type 2 using human induced pluripotent stem cell-derived alveolar organoids. Stem Cell Reports, 2019 Mar 5;12(3):431-440. doi: 10.1016/j.stemcr.2019.01.014. Epub 2019 Feb 14.

Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.

Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell, 2018 Dec 6;23(6):850-858.e4. doi: 10.1016/j.stem.2018.10.005. Epub 2018 Nov 15.

Zhitnyuk Y, Gee P, Lung MSY, Sasakawa N, Xu H, Saito H, Hotta A.

Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochem Biophys Res Commun, 505(4):1097-1102 (2018)

Seo H, Chen SJ, Hashimoto K, Endo H, Nishi Y, Ohta A, Yamamoto T, Hotta A, Sawaguchi A, Hayashi H, Koseki N, Murphy GJ, Fukuda K, Sugimoto N, Eto K.

A β1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. Blood Advances, 2018 Sep 11;2(17):2262-2272. doi: 10.1182/bloodadvances.2018019547.

Sasaki-Honda M, Jonouchi T, Arai M, Hotta A, Mitsuhashi S, Nishino I, Matsuda R, Sakurai H.

A patient-derived iPSC model revealed oxidative stress increases Facioscapulohumeral Muscular Dystrophy-causative DUX4. Human Molecular Genetics, 2018 Aug 9. doi: 10.1093/hmg/ddy293.

Honda-Ozaki F, Terashima M, Niwa A, Saiki N, Kawasaki Y, Ito H, Hotta A, Nagahashi A, Igura K, Asaka I, Li HL, Yanagimachi M, Furukawa F, Kanazawa N, Nakahata T, Saito MK.

Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress. Stem Cell Reports, 2018 May 1. pii: S2213-6711(18)30172-3. doi: 10.1016/j.stemcr.2018.04.004.

Ikeda T, Hikichi T, Miura H, Shibata H, Mitsunaga K, Yamada Y, Woltjen K, Miyamoto K, Hiratani I, Yamada Y, Hotta A, Yamamoto T, Okita K, Masui S.

Srf destabilizes cellular identity by suppressing cell-type-specific gene expression programs. Nature Communications, 2018 Apr 11;9(1):1387. doi: 10.1038/s41467-018-03748-1.

Oshima K, Saiki N, Tanaka M, Imamura H, Niwa A, Tanimura A, Nagahashi A, Hirayama A, Okita K, Hotta A, Kitayama S, Osawa M, Kaneko S, Watanabe A, Asaka I, Fujibuchi W, Imai K, Yabe H, Kamachi Y, Hara J, Kojima S, Tomita M, Soga T, Noma T, Nonoyama S, Nakahata T, Saito MK.

Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors. Biochem Biophys Res Commun., 2018 Mar 4;497(2):719-725. doi: 10.1016/j.bbrc.2018.02.139. Epub 2018 Feb 17.

Ishida K, Xu H, Sasakawa N, Lung MSY, Kudryashev JA, Gee P, Hotta A.

Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells. Scientific Reports., 2018 Jan 10;8:310. doi:10.1038/s41598-017-18568-4.

Kojima Y, Sasaki K, Yokobayashi S, Sakai Y, Nakamura T, Yabuta Y, Nakaki F, Nagaoka S, Woltjen K, Hotta A, Yamamoto T, Saitou M.

Evolutionarily distinctive transcriptional and signaling programs drive human germ cell lineage specification from pluripotent stem cells. Cell Stem Cell., 2017 Oct 5;21(4):517-532.e5. doi: 10.1016/j.stem.2017.09.005.

Chen Z, Chang WY, Etheridge A, Strickfaden H, Jin Z, Palidwor G, Cho JH, Wang K, Kwon SY, Doré C, Raymond A, Hotta A, Ellis J, Kandel RA, Dilworth FJ, Perkins TJ, Hendzel MJ, Galas DJ, Stanford WL.

Reprogramming progeria fibroblasts re-establishes a normal epigenetic landscape. Aging Cell., 2017 Jun 8. doi: 10.1111/acel.12621.

Takada S, Kambe N, Kawasaki Y, Niwa A, Honda-Ozaki F, Kobayashi K, Osawa M, Nagahashi A, Semi K, Hotta A, Asaka I, Yamada Y, Nishikomori R, Heike T, Matsue H, Nakahata T, Saito MK.

Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages. J Allergy Clin Immunol., 2017 Jun 3; pii: S0091-6749(17)30685-1. doi: 10.1016/j.jaci.2017.04.013.

Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo T, Kitaoka S, Ohta A, Tanaka A, Watanabe D, Morita M, Takuma H, Tamaoka A, Kunath T, Wray S, Furuya H, Era T, Makioka K, Okamoto K, Fujisawa T, Nishitoh H, Homma K, Ichijo H, Julien JP, Obata N, Hosokawa M, Akiyama H, Kaneko S, Ayaki T, Ito H, Kaji R, Takahashi R, Yamanaka S, Inoue H.

The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med., 2017 May 24;9(391). pii: eaaf3962. doi: 10.1126/scitranslmed.aaf3962.

Hirosawa M, Fujita Y, Parr CJC, Hayashi K, Kashida S, Hotta A, Woltjen K, Saito H.

Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. Nucleic Acids Res., 2017 May 19. doi: 10.1093/nar/gkx309.

Gee P, Xu H, Hotta A.

Cellular reprogramming, genome Editing, and alternative CRISPR Cas9 technologies for precise gene therapy of Duchenne muscular dystrophy. Stem Cells International., 2017 May 18; Article ID 8765154.

Imamura K, Sahara N, Kanaan NM, Tsukita K, Kondo T, Kutoku Y, Ohsawa Y, Sunada Y, Kawakami K, Hotta A, Yawata S, Watanabe D, Hasegawa M, Trojanowski JQ, Lee VM, Suhara T, Higuchi M, Inoue H.

Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Sci. Rep., 2016 Oct 10;6:34904.

Choi IY, Lim H, Estrellas K, Mula J, Cohen TV, Zhang Y, Donnelly CJ, Richard JP, Kim YJ, Kim H, Kazuki Y, Oshimura M, Li HL, Hotta A, Rothstein J, Maragakis N, Wagner KR, Lee G.

Concordant but varied phenotypes among Duchenne muscular dystrophy patient-specific myoblasts derived using a human iPSC-based model. Cell Rep., 2016 Jun 7;15(10):2301-12.

Komura S, Semi K, Itakura F, Shibata H, Ohno T, Hotta A, Woltjen K, Yamamoto T, Akiyama H, Yamada Y.

An EWS-FLI1-induced osteosarcoma model unveiled a crucial role of impaired osteogenic differentiation on osteosarcoma development. Stem Cell Reports., 2016 Mar 17.

Morita Y, Andersen P, Hotta A, Tsukahara Y, Sasagawa N, Hayashida N, Koga C, Nishikawa M, Saga Y, Evans SM, Koshiba-Takeuchi K, Nishinakamura R, Yoshida Y, Kwon C, Takeuchi JK.

Sall1 transiently marks undifferentiated heart precursors and regulates their fate. J Mol Cell Cardiol., 2016 Feb 11, 92:158-62.

Li HL, Gee P, Ishida K, and Hotta A.

Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system. Methods, 2015 Oct 23, pii: S1046-2023(15)30133-X.

Ishida K*, Gee P*, and Hotta A. (*: equal contribution)

Minimizing off-target mutagenesis risks caused by programmable nucleases. Int. J. Mol. Sci., 2015 Oct 16, 16 (10), 24751-24771

Hotta A, and Yamanaka S.

From genomics to gene therapy: induced pluripotent stem cells meet genome editing. Annu. Rev. Genet., 2015 Sep 25, 49:47-70.

Hotta A.

Genome editing gene therapy for Duchenne muscular dystrophy. J. Neuromuscul. Dis., 2015 Sep 22, 2 (4) 343-355

Ishikawa M, Ohnishi H, Skerleva D, Sakamoto T, Yamamoto N, Hotta A, Ito J, Nakagawa T.

Transplantation of neurons derived from human iPS cells cultured on collagen matrix into guinea-pig cochleae. J Tissue Eng. Regen. Med., 2015 Jul 24.

Iizuka H, Kagoya Y, Kataoka K, Yoshimi A, Miyauchi M, Taoka K, Kumano K, Yamamoto T, Hotta A, Arai S, Kurokawa M.

Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Experimental Hematology, 2015 June 11, 43(10): p849-57.

Fujita H, Esaki T, Masujima T, Hotta A, Kim SH, Noji H, Watanabe TM.

Comprehensive chemical secretory measurement of single cells trapped in a micro-droplet array with mass spectrometry. RSC Advances., 2015 Jan 20, 5(22):16968-71.

Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, Yamamoto T, Yamanaka S, and Hotta A.

Precise correction of the Dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports, 2015; Vol.4 (1): p143-154.

Rahmani W, Abbasi S, Hagner A, Raharjo E, Kumar R, Hotta A, Magness S, Metzger D, Biernaskie J.

Hair follicle dermal stem cells regenerate the dermal sheath, repopulate the dermal papilla, and modulate hair type. Dev. Cell, 2014; Vol.31 (5): p543-558

Matsui H, Fujimoto N, Sasakawa N, Ohinata Y, Shima M, Yamanaka S, Sugimoto M, and Hotta A

Delivery of full-length Factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A PLOS ONE, 2014; Vol.9 (8): e104957

Kondo T, Funayama M, Tsukita K, Hotta A Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H, Yamanaka S, and Inoue H

Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports, 2014; Vol.3 (2): p242-249.

Li HL, Nakano T, Hotta A

Genetic correction using engineered nucleases for gene therapy applications. Development Growth & Differentiation, 2014; Vol.56 (1): p63-77.

Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S, Takahash J

Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate. Stem Cell Reports, 2013; Vol.1 (4): p283-292.

Yamashita A, Liu S, Woltjen K, Thomas B, Meng G, Hotta A, Takahashi K, Ellis J, Yamanaka S, Rancourt DE.

Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells. Scientific Reports, 2013; Vol.3: 1978.

Tanaka A, Woltjen K, Miyake K, Hotta A, Ikeya M, Yamamoto T, Nishino T, Shoji E, Sehara-Fujisawa A,Manabe Y, Fujii N, Hanaoka K, Era T, Yamashita S, Isobe K, Kimura E, Sakurai H.

Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi myopathy in vitro. PLoS ONE, 2013; Vol.8 (4): e61540.

Fussner E, Djuric U, Strauss M, Hotta A, Perez-Iratxeta C, Lanner F, Dilworth FJ, Ellis J, Bazett-Jones DP.

Constitutive heterochromatin reorganization during somatic cell reprogramming. EMBO Journal, 2011; Vol.30 (9): p1778-1789.

Kinoshita T, Nagamatsu G, Kosaka T, Takubo K, Hotta, A, Ellis J, Suda T.

Ataxia-telangiectasia mutated (ATM) deficiency decreases reprogramming efficiency and leads to genomic instability in iPS cells. Biochem Biophys Res Commun, 2011 Apr 8;407(2):321-6

Cheung AY, Horvath LM, Grafodatskaya D, Pasceri P, Weksberg R,Hotta, A, Carrel L, Ellis J.

Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X–chromosome inactivation. Hum Mol Genet, 2011; Vol 20 (11): p2103-2115.

Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, Ellis J, Keller G.

Stage-specific optimization of Activin/Nodal and BMP signaling promotes efficient cardiovascular differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell, 2011; Vol.8 (2): p228-240.

Hotta A, Cheung AY, Farra N, Garcha K, Chang WY, Pasceri P, Stanford WL, Ellis J.

EOS lentiviral vector selection system for human induced pluripotent stem cells. Nature Protocols, 2009; Vol.4 (12): p1828-1844.

Rastegar M, Hotta A, Pasceri P, Makarem M, Cheung AY, Elliott S, Park KJ, Adachi M, Jones FS, Clarke ID, Dirks P, Ellis J.

MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy. PLoS ONE, 2009; Vol.4 (8): e6810.

Hotta A, Cheung AY, Farra N, Vijayaragavan K, Seguin CA, Draper JS, Pasceri P, Maksakova IA, Mager DL, Rossant J, Bhatia M, Ellis J.

Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nature Methods, 2009; Vol.6 (5): p370-376.

Hotta A, Ellis J.

Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. J Cell Biochem, 2008; Vol.105 (4): p940-948.

Buzina A, Lo MY, Moffett A, Hotta A, Fussner E, Bharadwaj RR, Pasceri P, Garcia-Martinez JV, Bazett-Jones DP, Ellis J.

β-globin LCR and intron elements cooperate and direct spatial reorganization for gene therapy. PLoS Genet, 2008; Vol.4 (4): e1000051.

Ellis J, Hotta A, Rastegar M.

Retrovirus silencing by an epigenetic TRIM. Cell, 2007; Vol.131 (1): p13-14.

Morshed M, Ando M, Yamamoto J, Hotta A, Kaneoka H, Kojima J, Nishijima K, Kamihira M, Iijima S.

YY1 binds to regulatory element of chicken lysozyme and ovalbumin promoters. Cytotechnology, 2006; Vol.52 (3): p159-170.

Hotta A, Saito Y, Kyogoku K, Kawabe Y, Nishijima K, Kamihira M, Iijima S.

Characterization of transient expression system for retroviral vector production. J Biosci Bioeng, 2006; Vol.101 (4): p361-368.

Hotta A, Ono K, Mizuarai S, Yamaguchi K, Nishijima K, Kamihira M, Iijima S.

Production of pharmaceutical proteins by transgenic avian. Animal Cell Technology: Basic & Applied Aspects, 2004; Vol.13: p299-303.

Hotta A, Kamihira M, Itoh K, Morshed M, Kawabe Y, Ono K, Matsumoto H, Nishijima K, Iijima S.

Production of anti-CD2 chimeric antibody by recombinant animal cells. J Biosci Bioeng, 2004; Vol.98 (4): p298-303.

Ono K, Kamihira M, Kuga Y, Matsumoto H, Hotta A, Itoh T, Nishijima K, Nakamura N, Matsuda H, Iijima S.

Production of anti-prion scFv-Fc fusion proteins by recombinant animal cells. J Biosci Bioeng, 2003; Vol.95 (3): p231-238.

著作物

堀田秋津

ゲノム編集による低抗原性iPS細胞の開発 再生医療 2020; Vol.19 (4): p106-114 (450-458).

堀田秋津

免疫汎用性向上を目指したHLA編集iPS細胞 実験医学増刊「新規の創薬モダリティ　細胞医薬」 2020; Vol. 38(17): p171-177 (2963-2969).

徐 淮耕, 堀田秋津

iPS細胞臨床応用をめざしたゲノム編集による低抗原性iPS細胞の作製 医学のあゆみ 2020; Vol.274 (3): p299-306.

渡邊 啓, 北 悠人, 奥嵜雄也

ゲノム編集を用いた筋ジストロフィー治療技術開発動向 医学のあゆみ 2020; Vol.273 (9): p869-876.

徐 淮耕, 堀田秋津

テーラーメイド医療を目指したゲノム編集iPS細胞 Precision Medicine, 2020; Vol.3 (6): p22-25 (520-523).

渡邊 啓, 北 悠人, 奥嵜雄也, 堀田秋津

ゲノム編集で挑む新時代の遺伝子治療研究 遺伝子医学, 2020; Vol.10 (2): p77-85.

北 悠人, 岩渕久美子, 堀田秋津

ゲノム編集技術の発展とその神経・筋疾患への応用 Clinical Neuroscience, 2020; Vol.38 (3): p323-329.

北 悠人, 渡邊 啓, 徐 淮耕, 鍵田明宏, 堀田秋津

iPS細胞における欠失挿入導入ゲノム編集実験 実験医学別冊「完全版 ゲノム編集実験スタンダード」, 2019年 p184-204.
山本 卓, 佐久間哲史 編

Ifuku M, Iwabuchi KA, Tanaka M, Lung MSY, Hotta A.

Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells. Methods Mol Biol., 2018;1828:191-217. doi: 10.1007/978-1-4939-8651-4_12.

奥嵜雄也, 堀田秋津

ゲノム編集の非ウイルス性送達法および臨床応用戦略 血液フロンティア, 2018; Vol.28 (07): p1077-1087.

岩渕久美子, 堀田秋津

12章　ゲノム編集によるデュシェンヌ型筋ジストロフィーの治療戦略 医療応用をめざすゲノム編集　最新動向から技術・倫理的課題まで, 2018; p122-136.
真下知士, 金田安史 編

鍵田明宏, 徐 淮耕, 堀田秋津

ゲノム編集技術を利用した筋ジストロフィー研究および治療戦略 実験医学増刊「超高齢社会に挑む骨格筋のメディカルサイエンス」, 2018; Vol.28 (3): p27-36 (p343-352).

岩渕久美子, 堀田秋津

ゲノム編集技術とその応用の現状 血液フロンティア, 2018; Vol.28 (03): p343-352.

堀田秋津

iPS細胞の遺伝子変異をゲノム編集で修復する ー疾患研究と遺伝子治療の最先端 生物の科学　遺伝, 2017; Vol.71 (05): p415-424.

井福正隆, 堀田秋津

iPS細胞とゲノム編集の融合による新展開 日本臨牀, 2017; Vol.75 (05): p788-794.

蒔田幸正, 穂積裕幸, 堀田秋津

筋ジストロフィー治療応用を目指したゲノム編集技術の開発動向 Clinical Calcium, 2017; Vol.27 (3): p67-75 (p391-399).

石田賢太郎, 徐 淮耕, 堀田秋津

第2章-8.　ヒトでのゲノム編集 -遺伝子治療応用へと動き出した現状 実験医学増刊号　"All About ゲノム編集" 2016年 Vol.34 No.20 p133-140. 真下知士, 山本 卓 編

堀田秋津

iPS細胞におけるゲノム編集 学友会会誌 2016年 Vol.36 p45-48.

徐 淮耕, 堀田秋津

Duchenne型筋ジストロフィーに対するゲノム編集戦略 医学のあゆみ, 2016; Vol.259 (1): p73-79.

李 紅梅,　堀田秋津

第2章　ヒト人工多能性幹細胞(iPS細胞)でのゲノム編集 実験医学別冊 "論文だけではわからない ゲノム編集成功の秘訣Q&A" 2015年11月号; p96-105. 山本 卓 編

堀田秋津,　石田賢太郎,　佐伯涼太

疾患iPS細胞研究を加速する遺伝子改変技術の進歩 病理と臨床, 2015年6月号; Vol.33 (6): p622-626.

津下 到,　鈴木茂彦,　内藤素子,　堀田秋津,　井上治久

患者由来iPS細胞を用いた神経疾患研究 医学のあゆみ, 2015; Vol.252 (7): p824-828.

李 紅梅,　佐伯涼太,　堀田秋津

第5章　幹細胞技術開発「再生医療に向けたゲノム編集技術」 実験医学増刊 "再生医療2015 幹細胞と疾患iPS細胞の研究最前線" 2015; Vol.33 (2): p194 (346)-200 (352).
岡野 栄之,　山中 伸弥 編

Li, LH and Hotta, A.

Chapter 3: Editing Cultured Human Cells: From Cell Lines to iPS Cells Targeted Genome Editing Using Site-Specific Nucleases, Jan 14th 2015; p45-69,
Editor: Takashi Yamanoto

堀田秋津

iPS細胞応用を加速するゲノム編集技術 医学のあゆみ, 2015; Vol.252 (2): p183-188.

Hotta A, Yamanaka S

Chapter 2: Induced Pluripotent Stem Cells Biomaterials and Regenerative Medicine, Oct 2014; Editor, Peter Ma

李 紅梅， 堀田秋津

CRISPR/Casを用いた遺伝子治療への展望 実験医学, 2014; Vol.32 (11): p220-224.

堀田秋津

細胞種変換を支える遺伝子導入技術 細胞, 2014; Vol.46 (5): p220-224.

李 紅梅，佐久間哲史,　堀田秋津,　山本 卓

遺伝子改変法４：TALENによる遺伝子ターゲティング ES・iPS細胞実験スタンダード, 2014年3月5日発行, 監修:中辻憲夫,　編集:末盛博文

李 紅梅，Knut Woltjen，高橋和利，山中伸弥，堀田秋津

TALENを用いたヒトiPS細胞におけるゲノム編集 細胞工学, 2013; Vol.32 (5): p526-531.

堀田秋津

iPS細胞の小分子制御 学術の動向, 2011; Vol.16 (5): p62-65.

Sciabica, K, Woltjen, K, Hotta, A.

Multiplex gene-expression assay for human induced Pluripotent stem cells. Genetic Engineering & Biotechnology News (GEN), 2010; Vol.30 (3).

Kawabe Y, Hotta A, Ono K, Esaka K, Nishijima K, Kamihira M, Iijima S

Production of chimeric antibodies by transgenic chicken bioreactors. Animal Cell Technology: Basic & Applied Aspects, 2006; Vol.14: p309-315.

Hotta A, Saito K, Nishijima K, Kamihira M, Iijima S

Preparation of high-titer retroviral vectors using transient expression system. Animal Cell Technology: Basic & Applied Aspects, 2006; Vol.14: p293-299.

Hotta, A, Ono, K, Mizuarai, S, Yamaguchi, K, Nishijima, K, Kamihira, M, Iijima, S.

Production of pharmaceutical proteins by transgenic avian. Animal Cell Technology: Basic & Applied Aspects, 2004; Vol.13: p299-303.